Bionano Genomics to Present at the 2022 Maxim Virtual Growth Conference
Bionano Genomics, known for its innovations in optical genome mapping, has announced that CEO Erik Holmlin will present at the 2022 Maxim Virtual Growth Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bionano Genomics, known for its innovations in optical genome mapping, has announced that CEO Erik Holmlin will present at the 2022 Maxim Virtual Growth Conference. This event will take place on March 30, 2022, at 12:30 PM PT/3:30 PM ET. The conference can be accessed via the M-Vest platform, where participants can register and view the presentation. Bionano aims to transform genome analysis through its Saphyr® system and NxClinical™ software, addressing critical questions in biology and medicine.
Details
News Market Reaction – BNGO
The recorded move for BNGO in the trading session of this news was +0.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, announced today that company management will present at the 2022 Maxim Virtual Growth Conference. Erik Holmlin, PhD, Bionano’s president and chief executive officer, will participate in a fireside chat on Wednesday, March 30th, 2022 at 12:30 pm PT/3:30 pm ET.
The conference is hosted on the M-Vest site. Interested parties can register for the conference and view the fireside chat here: https://m-vest.com/events/2022-virtual-growth-conference.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit bionanogenomics.com, lineagen.com or biodiscovery.com.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.